2 deals
Mirugen Secures A$4.5m to Pioneer Cell (Re)programming, and Welcomes Charlotte Casebourne Stock as Executive Chair
Mirugen, a Melbourne biotech spun out of an eye research institute, has closed a A$4.5m seed round with three backers and hired Charlotte Casebourne Stock as chair and acting chief executive.
Also cera.org.au·Brandon BioCatalyst portfolio·insightnews.com.au